Jaguar Health

JAGX

Market cap $2.03M

Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 22, 2026 Annual Meeting of Stockholders (the "Annual Meeting"), which was adjourned until June 8, 2026. Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting.

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS) Crofelemer development with novel formulations for different gastrointestinal disorders reflects a differentiated botanical drug platform integrating ethnobotanical medicine, sustainable harvesting, complex CMC, and novel bioassays to support approval under FDA botanical guidance Traditional knowledge of Croton lechleri use supported ethnobotanical research that led to development and approval of crofelemer, whose first in class anti-secretory mechanism was characterized through modern pharmacology and mechanism-based bioassays.

JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). "We are very happy that Jaguar has regained compliance with the Nasdaq listing criteria.

Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs.

Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference Company plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the quarter ended March 31, 2026 SAN FRANCISCO, CA / ACCESS Newswire / May 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 26, 2026 at 8:30 a.m. Eastern to review first-quarter 2026 financials and provide corporate updates, and that Lisa Conte, Jaguar's founder, president and CEO, will present virtually on Thursday, May 28, 2026 at 10 a.m.

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and no approved therapies, requiring lifelong parenteral support (PS) SAN FRANCISCO, CA / ACCESS Newswire / May 19, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind crossover clinical trial has entered the active treatment only single-blind extension to evaluate the longer term safety and efficacy of crofelemer powder for oral solution as adjunctive treatment to parenteral support (PS) to support regulatory submissions for the drug to treat this serious unmet medical need. The trial is being conducted at multiple centers with appropriate regulatory approvals in the United States (US), European Union (EU), and United Arab Emirates (UAE).

SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Market ("Nasdaq"). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel ("Panel") granting the Company's request for an extension to demonstrate compliance with the Nasdaq Listing Rules.

Jaguar Health Inc (NASDAQ:JAGX) shares are climbing Wednesday morning. The momentum follows the company's announcement of preliminary discussions with the FDA to evaluate a Breakthrough Therapy Designation for oral liquid crofelemer.

Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy Designation Crofelemer has demonstrated meaningful reductions in weekly PS needs in two pediatric MVID patients with initial results to be presented at ESPGHAN 2026 SAN FRANCISCO, CA / ACCESS Newswire / May 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals Inc., announced that the Company recently held a preliminary discussion with the Division of Gastroenterology at U.S. Food and Drug Administration (FDA) to evaluate the possibility of a Breakthrough Therapy Designation (BTD) for oral liquid crofelemer as an adjunctive therapy to PS for the treatment of pediatric patients with intestinal failure (IF) due to microvillus inclusion disease (MVID), an ultrarare congenital disorder with a lethal natural history requiring lifelong PS. Crofelemer has demonstrated preliminary clinical proof of concept (POC) in pediatric MVID patients in two open-label studies, with meaningful reductions in weekly PS requirements for the two MVID patients.